Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the ...
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Investor's Business Daily on MSN39m
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback